Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Pharma fights Mass. disclosure bill
Drugmakers are kicking back at a Massachusetts marketing-and-disclosure bill that we reported on a few days ago. The outright ban on gifts to docs didn't make it into the compromise measure, but pharma isn't happy nonetheless. The bill would require disclosure of any payment or gift of $50 or more--and companies are saying that handing over that info would have a "chilling effect" on life sciences in the state.
How so? Well, PhRMA is pointing to language in the bill requiring disclosure of the "nature and purpose" of every doc payment. The industry association says that could be construed to mean that clinical trial data would have to be an open book if docs were paid to be part of those trials. We think that's stretching a bit--maybe to scare the governor into vetoing the bill?--but then again, we aren't lawyers.
- read the post at Pharmalot
Related Articles:
Massachusetts OKs drug marketing bill
Doc disclosure gets boost from AZ, Merck
Pharma faces payment disclosure law
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


